Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Casodex(R) Tablets
July 07 2009 - 10:44AM
PR Newswire (US)
DETROIT, July 7 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical
Laboratories, Ltd. (NYSE Amex: CPD) has launched Bicalutamide
tablets on behalf of Sun Pharmaceutical Industries Ltd. (Sun
Pharma), immediately following Sun Pharma's recently received
approval from the US Food and Drug Administration (FDA) for its
Abbreviated New Drug Application (ANDA) for generic Casodex(R)
tablets. Bicalutamide tablets are an androgen receptor inhibitor
indicated for use in combination therapy with a luteinizing
hormone-releasing hormone (LHRH) analog for the treatment of Stage
D2 metastatic carcinoma of the prostate. This generic version of
Bicalutamide 50 mg tablets is bioequivalent to Casodex(R) which is
a registered trademark of AstraZeneca group of companies. According
to IMS Data, Casodex had US sales of approximately $314 million for
the calendar year of 2008. Daniel H. Movens, Caraco's Chief
Executive Officer, said, "We are pleased to add this product to our
portfolio by launching Bicalutamide tablets immediately to the
marketplace. We continue to focus on working towards expanding our
product offering as quickly and effectively as possible."
Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops,
manufactures, markets and distributes generic and private-label
pharmaceuticals to the nation's largest wholesalers, distributors,
drugstore chains and managed care providers. Safe Harbor: This news
release contains forward-looking statements made pursuant to the
safe-harbor provisions of the Private Securities Litigation Reform
Act of 1995. Such statements are based on management's current
expectations and are subject to risks and uncertainties that could
cause actual results to differ materially from those described in
the forward-looking statements. These risks and uncertainties are
contained in the Corporation's filings with the Securities and
Exchange Commission and include, but are not limited to:
information of a preliminary nature that may be subject to
adjustment, potentially not obtaining or delay in obtaining FDA
approval for new products, governmental restrictions on the sale of
certain products, development by competitors of new or superior
products or cheaper products or new technology for the production
of products, the entry into the market of new competitors, market
and customer acceptance and demand for new pharmaceutical products,
availability of raw materials, timing and success of product
development and launches, dependence on few products generating
majority of sales, product liability claims for which the Company
may be inadequately insured, and other risks identified in this
report and from time to time in our periodic reports and
registration statements. These forward-looking statements represent
our judgment as of the date of this report. We disclaim, however,
any intent or obligation to update our forward-looking statements.
DATASOURCE: Caraco Pharmaceutical Laboratories, Ltd. CONTACT:
Daniel Movens, +1-313-871-8400, or Thomas Versosky,
+1-313-556-4150, both of Caraco Pharmaceutical Web Site:
http://www.caraco.com/
Copyright